# US 2023/0398116 A1 · Agent for reversing resistance to anticancer drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398116 A1
- Document ID: US20230398116A1
- Status: Published application
- Kind: A1
- Application number: 18/009,083
- Filed: 2021-06-07
- Published: 2023-12-14
- Earliest claimed: 2020-06-08
- Assignees: Y's AC Co., Ltd.; Juntendo Educational Foundation
- Applicants: Y's Ac Co., Ltd.; Juntendo Educational Foundation
- Inventors: Chikao Morimoto; Kei Ohnuma; Ryo Hatano; Takumi Itoh; Yutaro Kaneko
- Web page: https://patentgrep.com/patent/US20230398116A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- C07K 14/54: Interleukins [IL]
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/244: {Interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is the present invention focusing on roles of IL-26 present in humans but not in mice by characterizing molecular mechanisms involved in interspecies differences in terms of efficacy of EGFR-TKI. The present inventors found that human cancers are exposed to IL-26 in a tumor microenvironment (TME), activating the EGFR-TKI bypass pathway, while suppression of IL-26 overcomes EGFR-TKI resistance in cancers. Furthermore, the present inventors identified EphA3 as a new functional receptor for IL-26 of TNBC. Therefore, the present invention provides a pharmaceutical composition for use in combination with an anticancer drug for treating cancer in a patient, the pharmaceutical composition containing a drug that reverses resistance to the anticancer drug by IL-26 as an active ingredient. Furthermore, the present invention provides a humanized anti-IL-26 antibody, and a therapeutic or preventive agent for refractory immune disorders or cancer using the antibody.

## Claims

### Claim 1

A pharmaceutical composition for use in combination with an anticancer drug, the pharmaceutical composition comprising, as an active ingredient, a drug that reverses resistance to the anticancer drug due to IL-26 in a cancer.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the cancer is breast cancer, wherein the breast cancer is a human epidermal growth factor receptor 2 (HER2) negative cancer, or wherein the cancer is estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative (triple negative breast cancer (TNBC)).

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the cancer is a cancer expressing EphA3.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the cancer is a cancer having a low sensitivity to the anticancer drug or exhibiting resistance to the anticancer drug.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the low sensitivity or the resistance to the anticancer drug is caused by IL-26 or phosphorylation of AKT and/or JNK due to IL-26 or wherein the low sensitivity or the resistance to the anticancer drug is due to an interaction between IL-26 and EphA3.

### Claim 8

(canceled)

### Claim 9 (depends on 7)

The pharmaceutical composition according to claim 7, wherein IL-26 is produced by CD4+ T-cells or macrophages.

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the anticancer drug is a tyrosine kinase inhibitor.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the tyrosine kinase inhibitor is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selected from gefitinib, erlotinib, afatinib maleate, osimertinib mesylate, and dacomitinib hydrate.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the drug that reverses the resistance to the anticancer drug due to IL-26 is a drug that inhibits or reduces the interaction between ephrintype-Areceptor3 (EphA3) and IL-26.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the drug that inhibits or reduces the interaction between EphA3 and IL-26 is an antibody that inhibits the binding between EphA3 and IL-26, a humanized antibody, or a fragment thereof.

### Claim 15 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the drug that reverses the resistance to the anticancer drug due to IL-26 is an anti-IL-26 antibody, a humanized antibody or a fragment thereof.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, wherein the anti-IL-26 antibody is an antibody produced from a hybridoma deposited as Accession Nos. NITEP-02577, NITEP-02578, NITEP-02579, or NITEP-02580, an antibody having complementarity determining regions of a heavy chain and a light chain thereof, or an antibody having variable regions of a heavy chain and a light chain thereof.

### Claim 17 (depends on 15)

The pharmaceutical composition according to claim 15, wherein the anti-IL-26 antibody is an antibody containing a heavy chain variable region including an amino acid sequence described in SEQ ID NO:2 or 12 and a light chain variable region including an amino acid sequence described in SEQ ID NO:4 or 14, respectively, or an antibody having complementarity determining regions of a heavy chain and a light chain thereof.

### Claim 18 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the drug that reverses the resistance to the anticancer drug due to IL-26 is an anti-EphA3 antibody or a soluble EphA3.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The pharmaceutical composition according to claim 1, being an agent for improving a sensitivity of cancer cells to the anticancer drug, a proliferation inhibitor for cancer cells, or a combination thereof, and/or wherein the cancer cells have a low sensitivity to the anticancer drug or exhibit the resistance to the anticancer drug.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered simultaneously with the anticancer drug, after administration of the anticancer drug, or before administration of the anticancer drug.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

A method for improving responsiveness to an anticancer drug in cancer patients having a low sensitivity to the anticancer drug or exhibiting resistance to the anticancer drug, the method comprising inhibiting IL-26 in a cancer microenvironment of the cancer patients.

### Claim 29 (depends on 28)

The method according to claim 28, comprising inhibiting or reducing the interaction between EphA3 and IL-26 by inhibiting IL-26.

### Claim 30

A method for treating cancer in cancer patients having a low sensitivity to an anticancer drug or exhibiting resistance to an anticancer drug, the method comprising inhibiting IL-26 of the cancer patients and administering an anticancer drug to the cancer patients.

### Claim 31 (depends on 30)

The method according to claim 30, comprising inhibiting or decreasing the interaction between EphA3 and IL-26 by inhibiting or decreasing IL-26.

### Claim at position 32

-43. (canceled)
